Administration Core
行政核心
基本信息
- 批准号:10512618
- 负责人:
- 金额:$ 792.59万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-16 至 2025-04-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAntiviral AgentsAwardBasic ScienceBiologicalBiological SciencesBudgetsCollaborationsCommunicationCommunitiesDataDevelopmentElectronic MailEmerging TechnologiesEnsureEnvironmentEvaluationEventFeedbackFosteringFundingFutureGoalsGrantHuman ResourcesInstitutesInstitutionLeadLeadershipMentorsMissionMonitorNational Institute of Allergy and Infectious DiseaseProgram Research Project GrantsPublicationsReportingResearchResearch PersonnelResearch Project GrantsScheduleScientistSiteTechnologyUnited States National Institutes of HealthWritingcareerdesigndiversity and equitydrug developmentdrug discoveryexperienceindustry partnerinnovationinsightinterestinternational partnershipmeetingsmembernew technologypandemic diseaseprogramsrecruitresponsesummer internshipsymposiumtherapeutic targetunderrepresented minority studentweb site
项目摘要
ADMINISTRATIVE CORE
SUMMARY
The mission of the Administrative Core is to support and promote the scientific and collaborative goals of the
QCRG Pandemic Response Program. The Core will provide leadership that ensures strong oversight and
representation of all stakeholders in decisions and facilitates the integration of Research Projects and
Technology Cores. Day-to-day activities will be coordinated by the Center Director (Dr. Nevan Krogan), who
has extensive experience leading and managing large research centers, and the Administrative Core Co-
Investigators (Drs. Lorena Zuliani-Alvarez and Manon Eckhardt). They will be supported by the UCSF
Quantitative Biosciences Institute (QBI) administrative team. Evaluation of progress toward the Center’s goals
as well as budgeting and long-term planning of center activities will be performed by the Executive Committee
(EC), consisting of the Director and Drs. Melanie Ott, Kevan Shokat and Brian Shoichet. The EC will
communicate progress to our commercial partner, Roche, and meet with regulatory advisors once a year. As a
first task of the Executive Committee (EC), a Scientific Advisory Board (SAB) will be formed to review progress
of the program and future plans. The Administrative Core will be responsible for managing QCRG Consortia
with support of the QBI Finance Team. Supported by the QBI Media and Events team, the Administrative Core
will organize and manage a number of regularly scheduled meetings for the EC, the entire QCRG, and the wider
research community to facilitate communication amongst members and scientific exchange, as well as maintain
the QCRG website and shared file servers. To provide formal site review and involvement with NIAID staff, the
Core will organize an annual SAB Meeting, in which the PIs and key personnel will meet with the SAB and NIAID
program staff to review the Center’s activities. The Administrative Core will further design, solicit and manage
the Developmental Research Project and Mentored Project programs to adapt the Center’s goals to emergent
technologies and scientific advancements, attract new Investigators, and support early career QCRG scientists.
行政核心
总结
行政核心的使命是支持和促进科学和协作的目标,
QCRG流行病应对计划。核心将发挥领导作用,确保强有力的监督,
在决策中代表所有利益相关者,并促进研究项目的整合,
技术核心。日常活动将由中心主任(Nevan Krogan博士)协调,
拥有丰富的经验,领导和管理大型研究中心,和行政核心公司,
研究者(洛雷纳Zuliani-Alvarez和Manon Eckhardt博士)。他们将得到加州大学旧金山分校的支持
定量生物科学研究所(QBI)行政团队。评价实现中心目标的进展情况
以及中心活动的预算和长期规划将由执行委员会执行
(EC)由主任和Melanie Ott、Kevan Shokat和Brian Shoichet博士组成。教统会将
与我们的商业合作伙伴罗氏沟通进展情况,并每年与监管顾问会面一次。作为
执行委员会(EC)的第一项任务是成立一个科学咨询委员会(SAB),以审查进展情况
计划和未来的计划。行政核心将负责管理QCRG联盟
在QBI财务团队的支持下。在QBI媒体和活动团队的支持下,
将为EC、整个QCRG和更广泛的组织和管理一些定期会议
促进成员之间的沟通和科学交流,并保持
QCRG网站和共享文件服务器。为了提供正式的现场审查和与NIAID工作人员的参与,
核心将组织年度SAB会议,PI和关键人员将在会议上与SAB和NIAID会面
项目组负责人对中心的活动进行审查。行政核心将进一步设计、征求和管理
发展研究项目和指导项目计划,以适应中心的目标,以紧急
技术和科学进步,吸引新的研究人员,并支持早期职业QCRG科学家。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Nevan J Krogan其他文献
Nevan J Krogan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Nevan J Krogan', 18)}}的其他基金
HARC: HIV accessory and regulatory complexes
HARC:HIV 附件和调节复合体
- 批准号:
10506980 - 财政年份:2022
- 资助金额:
$ 792.59万 - 项目类别:
Core 1: Functional Genomics and Proteomics
核心1:功能基因组学和蛋白质组学
- 批准号:
10704617 - 财政年份:2022
- 资助金额:
$ 792.59万 - 项目类别:
Core 1: Functional Genomics and Proteomics
核心1:功能基因组学和蛋白质组学
- 批准号:
10525592 - 财政年份:2022
- 资助金额:
$ 792.59万 - 项目类别:
International West Africa Symposium and Workshop on Infectious Diseases
国际西非传染病研讨会暨讲习班
- 批准号:
10540552 - 财政年份:2022
- 资助金额:
$ 792.59万 - 项目类别:
HARC: HIV accessory and regulatory complexes
HARC:HIV 附件和调节复合物
- 批准号:
10666644 - 财政年份:2022
- 资助金额:
$ 792.59万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 792.59万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 792.59万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 792.59万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 792.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 792.59万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 792.59万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 792.59万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 792.59万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 792.59万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 792.59万 - 项目类别:














{{item.name}}会员




